英矽智能(3696)公布，与武田制药达成一项价值6亿美元的AI赋能药物发现战略合作，据明报报道，双方将依托英矽智能的Pharma.AI平台，在武田制药选定的疾病治疗领域共同推进候选药物研发。
英矽智能称，合作旨在针对具备高潜力的治疗靶点，发现具有临床差异化优势的候选药物。
AI趋势 | 英矽智能与武田制药达成6亿美元AI药物发现合作
2026-07-02 01:41:08
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Strategy称STRC交易目标99至100美元
